Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout

Immunostep

Immunostep is a Spanish biotechnology company driving the biomedical research and diagnostic solutions since 2001. They specialise in offering flow cytometry solutions that can improve early and non-invasive diagnostic solution in oncology, immunology and infectious disease space. They offer a wide array of assay kits for cell analysis by flow cytometry for apoptosis detection, platelet analysis and haematology analysis which includes platelet associated immunoglobulin detection kits for thrombocytopenia diagnosis and basophil detection kits to identify allergen stimulation in cells.

View all Immunostep Products
Immunostep

At present they have extended their portfolio to support Oncology by offering high-resolution flow cytometry antibodies for the detection of CAR-T cells during development as well as to characterise Tumour associated macrophages in blood.

They have over 900 publications featuring their products and in 2017 introduced Custom Exosome services that include isolation, purification including analyses of purity and composition to quantify exosomal cargo.

As a response to SARs-CoV-2 global emergency they also developed ELISA product line to improve serological testing performance and helped build clinical investigation around Covid-19 disease by offering Multiplex IgG+IgA+IgM, ELISA Spike IgG and ELISA Mpro IgG

Immunostep’s mission is to improve early stage and non-invasive diagnostic solution through their wide range of antibodies, buffers and assay kits highly suited for Flow cytometry applications for Oncology, Immunology, Haematology and Infectious Disease.

Their assay kits are effective for different disease diagnosis for research purpose and are great tool for cell cycle stage characterisation and quantification for Apoptosis, including identification of Stem Cells, Platelets and to distinguish other immune cell types through their wide range of CD marker antibodies.

The range of Assay kits they offer are listed here:


 

Mechanism

Apoptosis Assay Kit 

Combined detection of apoptosis and necrosis by fluorescent vital double staining with Annexin V including FITC or PE or Annexin V with PI or 7-AAD

MitoStep Kit 

It measures changes in the mitochondrial membrane potential with a solution of the cationic cyanine dye DiIC1(5)

HeMoStep Kit

Quantitative measurement of blood contamination of cerebrospinal fluid (CSF) samples by flow cytometry to improve the diagnosis of leptomeningeal disease in patients with B and T cell lymphomas and acute leukaemia of lymphoid and myeloid origin.

Baso-Step Kit 

Flow cytometry test of IgE-mediated allergic reactions by the analysis of CD63 antigen surface on basophils upon allergen stimulation

Stem Cell Kit 

Kit allows the identification of CD34 + cells and link together their number with the identified known number of spheres discriminating between viable and non-viable cells

Trombo Step Kit 

Detection of autoantibodies reacting with specific platelet receptors. The kit contains an R-phycoerythrin (R-PE) conjugated monoclonal antibody, which recognizes a platelet specific antigen. The kit also contains polyclonal antibodies conjugated with FITC against total human immunoglobulins, human IgA, IgM and IgG. 

With Immunotherapy becoming a crucial diagnostic solution in Oncology, Immunostep now offers Recombinant Fc-Tag CD19 protein (CD19p) and BCMA protein (BCMAp) for the detection and characterisation of CAR-T cells from challenging cell population.

The Key benefits of these antibodies compared to other competitor assay solutions are listed below:

Single reagent for direct and specific recognition of challenging cell population - Recombinant Fc-Tag CD19 protein (CD19p) and BCMA protein (BCMAp) has been labelled, by a proprietary process, with R-Phycoerythrin fluorochrome (R-PE or PE) or FITC, obtaining a conjugate that is able to be recognised by CAR T-Cells and separates them efficiently without any secondary reagent.

Simple 1 hour protocol with direct CAR-T separation labelling- The reagent is supplied in aqueous solution for direct cell labelling with 5μl of it. This, with the use of an antibody panel to discriminate T-Cells, is sufficient to separate those which have CAR in just a 30-minute incubation at room temperature (RT) spending around 1 hour of complete protocol, whereas other protocols spend the same time just to label the specific population. 

With new developments of Oncology detection also gaining momentum in exosome research Immunostep has also introduced Exosome custom services and Exosome isolation products with the potential to quantify exosome vesicles in any kind of sample for characterisation, purification and isolation as listed below:


ExoStep Detection Assay

The kit is a simple immunobead assay for isolation/detection of exosome, using a bead-bound anti-CD63 capture antibody and a fluorochrome conjugated anti-CD81 detection antibody. The kit provides reproducible results and can be run in parallel to exosome immunophenotyping.

Exosome Isolation Products 

Immunoaffinity Capture beads like CD274, CD326, CD63, CD81, CD9 for detection of vesicles

Lyophilised Exosome Standards 

Standards for different cell lines from RPMI, Caco2, serum, HT-29, PC-3 and many more including MSC derived as well  

Exosome Buffers

Range of exosome solutions are available such as Detachment solution and Precipitation solutions for different sample types such as only Plasma, Plasm+Serum, Cell culture+Urine

Immunostep CD Markers

2BScientific, in partnership with Immunostep, offers a broad range of validated CD markers designed to assess cell populations, viability, and abnormalities for the detection of malignancies, immune deficiencies, and infections.

Immunostep CD Markers

CAR T cell therapy from Immunostep

CAR T cell therapy is based on the removal of T cells from the patient, the introduction of a specific Chimeric Antigen Receptor (CAR) of a protein present on cancer cells (e.g., CD19), and the subsequent reinfusion of these modified cells, now called CAR T cells, into the patient so that they recognise the target cells and eliminate them.

This therapy has become relevant due to its effectiveness, so CAR T cell detection tools have become a critical need, both to check that they have been modified correctly and to monitor them after reinfusion, since they have a limited shelf life.

CAR T cell therapy from Immunostep